Depression is a pervasive mental illness with a
prevalence of about nine percent of the Canadian population (Van Ameringen et al.,
2008). Depression commonly presents with several
chronic symptoms that can severely impact the
quality of life and mental well-being, such as intrusive thoughts, flashbacks,
irritability, anxiety, and sleep disturbances (Sharpless
& Barber, 2011). Military
veterans are notably present with much higher rates of depressionthan civilians (Veterans Affairs Canada, 2019).
There is no single effective treatment,
and persons with depression might receive multiple modes of treatment in
combination. To date, few studies have characterized the demographic characteristics of medical marijuana
patients or assessed them forpre-post changes
in well-being. A mixed methods study was conducted tobetter understand therapeutic benefits for
patients. Here, we aimed to de
References
[1]
Allan, G. M., Ramji, J., Perry, D., Ton, J., Beahm, N. P., Crisp, N., & Lindblad, A. J. (2018). Simplified Guideline for Prescribing Medical Cannabinoids in Primary Care. Canadian Family Physician, 64, 111-120.
[2]
Berkwits, M., & Inui, T. S. (1998). Making Use of Qualitative Research Techniques. Journal of General Internal Medicine, 13, 195-199. https://doi.org/10.1046/j.1525-1497.1998.00054.x
[3]
Booth, C. M., & Tannock, I. F. (2014). Randomised Controlled Trials and Population-Based Observational Research: Partners in the Evolution of Medical Evidence. British Journal of Cancer, 110, 551-555. https://doi.org/10.1038/bjc.2013.725
[4]
Bouso, J. C., Jiménez-Garrido, D., Ona, G., Woznica, D., Dos Santos, R. G., Hallak, J. E., & Farré, M. (2020). Quality of Life, Mental Health, Personality and Patterns of Use in Self-Medicated Cannabis Users with Chronic Diseases: A 12-Month Longitudinal Study. Phytotherapy Research, 34, 1670-1677. https://doi.org/10.1002/ptr.6639
[5]
Carrieri, V., Madio, L., & Principe, F. (2020). Do-It-Yourself Medicine? The Impact of Light Cannabis Liberalization on Prescription Drugs. Journal of Health Economics, 74, Article ID: 102371. https://doi.org/10.1016/j.jhealeco.2020.102371
[6]
Casarett, D. J., Beliveau, J. N., & Arbus, M. S. (2019). Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms. Journal of Palliative Medicine, 22, 1180-1184. https://doi.org/10.1089/jpm.2018.0658
[7]
Crowell, T. L. (2017). Therapeutic Value of Medical Marijuana in New Jersey Patients: A Community Partnership Research Endeavor. Journal of Allied Health, 46, 232-240.
[8]
El-Gabalawy, R., Thompson, J. M., Sweet, J., Erickson, J., Mackenzie, C. S., Pietrzak, R. H., & Sareen, J. (2015). Comorbidity and Functional Correlates of Anxiety and Physical Conditions in Canadian Veterans. Journal of Military, Veteran and Family Health, 1, 37-46. https://doi.org/10.3138/jmvfh.2014-03
[9]
Hindocha, C., Cousijn, J., Rall, M., & Bloomfield, M. A. P. (2020). The Effectiveness of Cannabinoids in the Treatment of Posttraumatic Stress Disorder (Depression): A Systematic Review. Journal of Dual Diagnosis, 16, 120-139. https://doi.org/10.1080/15504263.2019.1652380
[10]
Hopman, W. M., Thompson, J. M., Sweet, J., VanTil, L., VanDenKerkhof, E. G., Sudom, K., & Pedlar, D. (2015). Multivariate Assessment of Health-Related Quality of Life in Canadian Armed Forces Veterans after Transition to Civilian Life. Journal of Military, Veteran and Family Health, 1, 61-70. https://doi.org/10.3138/jmvfh.2986
[11]
Horne, R. (2020). Adherence to Medication: A Review of Existing Research (pp. 285-310). CRC Press. https://doi.org/10.1201/9781003072348-15
[12]
Kalaba, M., & Ware, M. A. (2022). Cannabinoid Profiles in Medical Cannabis Users: Effects of Age, Gender, Symptoms, and Duration of Use. Cannabis and Cannabinoid Research, 7, 840-851. https://doi.org/10.1089/can.2020.0120
[13]
Kaufmann, C. N., Kim, A., Miyoshi, M., & Han, B. H. (2022). Patterns of Medical Cannabis Use among Older Adults from a Cannabis Dispensary in New York State. Cannabis and Cannabinoid Research, 7, 224-230. https://doi.org/10.1089/can.2020.0064
[14]
Lim, K., See, Y. M., & Lee, J. (2017). A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders. Clinical Psychopharmacology and Neuroscience, 15, 301-312. https://doi.org/10.9758/cpn.2017.15.4.301
[15]
MacCallum, C. A., & Russo, E. B. (2018). Practical Considerations in Medical Cannabis Administration and Dosing. European Journal of Internal Medicine, 49, 12-19. https://doi.org/10.1016/j.ejim.2018.01.004
[16]
Orsolini, L., Chiappini, S., Volpe, U., De Berardis, D., Latini, R., Papanti, G. D., & Corkery, J. M. (2019). Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. Medicina, 55, Article 525. https://doi.org/10.3390/medicina55090525
[17]
Petersen, M., Koller, K., Straley, C., & Reed, E. (2021). Effect of Cannabis Use on Depression Treatment Outcomes in Veterans. Mental Health Clinician, 11, 238-242. https://doi.org/10.9740/mhc.2021.07.238
[18]
Schnurr, P. P., Lunney, C. A., Bovin, M. J., & Marx, B. P. (2009). Posttraumatic Stress Disorder and Quality of Life: Extension of Findings to Veterans of the Wars in Iraq and Afghanistan. Clinical Psychology Review, 29, 727-735. https://doi.org/10.1016/j.cpr.2009.08.006
[19]
Sharpless, B. A., & Barber, J. P. (2011). A Clinician’s Guide to PTSD Treatments for Returning Veterans. Professional Psychology: Research and Practice, 42, 8-15. https://doi.org/10.1037/a0022351
[20]
Singh, J. A., Borowsky, S. J., Nugent, S., Murdoch, M., Zhao, Y., Nelson, D. B., & Nichol, K. L. (2005). Health-Related Quality of Life, Functional Impairment, and Healthcare Utilization by Veterans: Veterans’ Quality of Life Study. Journal of the American Geriatrics Society, 53, 108-113. https://doi.org/10.1111/j.1532-5415.2005.53020.x
[21]
Spitzer, R. L. (1999). Patient Health Questionnaire: PHQ. New York State Psychiatric Institute.
[22]
Takakuwa, K. M., Hergenrather, J. Y., Shofer, F. S., & Schears, R. M. (2020). The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain: How Cannabis Diminished Prescription Opioid Usage. Cannabis and Cannabinoid Research, 5, 263-270. https://doi.org/10.1089/can.2019.0039
[23]
Thompson, J. M., VanTil, L. D., Zamorski, M. A., Garber, B., Dursun, S., Fikretoglu, D., & Sudom, K. (2016). Mental Health of Canadian Armed Forces Veterans: Review of Population Studies. Journal of Military, Veteran and Family Health, 2, 70-86. https://doi.org/10.3138/jmvfh.3258
[24]
Van Ameringen, M., Mancini, C., Patterson, B., & Boyle, M. H. (2008). Post-Traumatic Stress Disorder in Canada. CNS Neuroscience & Therapeutics, 14, 171-181. https://doi.org/10.1111/j.1755-5949.2008.00049.x
Veterans Affairs Canada (VAC) (2021). Cannabis for Medical Purposes. https://www.veterans.gc.ca/eng/about-vac/research/research-directorate/publications/reports/cmp2018
[27]
Walsh, Z., Gonzalez, R., Crosby, K., Thiessen, M. S., Carroll, C., & Bonn-Miller, M. O. (2017). Medical Cannabis and Mental Health: A Guided Systematic Review. Clinical Psychology Review, 51, 15-29. https://doi.org/10.1016/j.cpr.2016.10.002
[28]
Ware, M. A., Adams, H., & Guy, G. W. (2005). The Medicinal Use of Cannabis in the UK: Results of a Nationwide Survey. International Journal of Clinical Practice, 59, 291-295. https://doi.org/10.1111/j.1742-1241.2004.00271.x
